Medical Firm Grounded: DEA Yanks Registration Over Lax Checks
Published Date: 1/27/2026
Notice
Summary
Allied Medical Products, Inc. lost its DEA registration because it didn’t properly check its customers before selling controlled substances and let someone else use its account. This means Allied Medical can no longer legally distribute these drugs, effective immediately. The decision protects public safety and sends a clear message about following the rules.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked — No Drug Distribution
Allied Medical Products, Inc. (DEA Certificate No. RA0235146) had its DEA registration revoked, so it cannot legally distribute controlled substances after February 26, 2026. The revocation follows a finding that Allied failed to perform required customer due diligence and allowed another entity to use its purchasing account.
Pending DEA Applications Denied in California
The Agency denied any pending applications by Allied Medical Products, Inc. to renew or modify its DEA registration, as well as any other pending application for additional registration in California, effective February 26, 2026. Those applications will not proceed while the denial stands.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2026-01493 — Cessation of Trustee Terms
Two trustees at the Institute of American Indian and Alaska Native Culture and Arts Development will finish their terms on May 19, 2026. This means new trustees will need to step up soon to keep the board strong and creative. If you’re involved or interested, mark your calendar and get ready for some fresh faces and ideas!
Next: 2026-01498 — Complete Care Pharmacy, LLC; Decision and Order
Complete Care Pharmacy in New Mexico lost its DEA license because its owner filled 26 drug prescriptions without having the legal authority to do so. This means the pharmacy can no longer handle controlled substances, impacting its business immediately. Anyone relying on this pharmacy for such medications will need to find a new provider fast.